NCT00623701

Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation

A Multicentre, Multinational, Placebo-controlled, Double-blind, Randomized Study to Evaluate Efficacy and Safety of a Perennial, Sublingual, Specific Immunotherapy in Patients With Rhinoconjunctivitis With/Without Controlled Asthma Caused by Grass Pollen

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Allergopharma GmbH & Co. KG · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and Safety from a high-dosed sublingual grass pollen preparation

Conditions

• Allergy
• Rhinitis
• Conjunctivitis

Interventions

Type	Name	Description
BIOLOGICAL	Allerslit forte	sublingual placebo preparation, daily
BIOLOGICAL	Allerslit forte	Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily

Timeline

• Start date: 2008-03-01
• Primary completion: 2011-10-01
• Completion: 2012-10-01
• First posted: 2008-02-26
• Last updated: 2013-11-08

Locations

1 site across 1 country: Germany